KLOW

The letters are commonly read as KPV, GHK-Cu (or 'GLOW'), BPC-157 and TB-500, but there is no standards body behind the name. Amounts and ratios are formulation-specific where they are stated at all, so this profile does not describe a single composition.

• KPV — read the evidence profile
• GHK-Cu — read the evidence profile
• BPC-157 — read the evidence profile
• TB-500 — read the evidence profile

  TB-500 naming is itself ambiguous: material sold under that name may be a thymosin beta-4 fragment rather than the full peptide, and the two are not interchangeable in the research literature.

Blends are mixtures sold under a nickname. The name is chosen by whoever is selling it, so two vials with the same name can contain different ingredients in different amounts. Any evidence level shown here describes the combined marketed mixture, which is almost always untested as a mixture.

• No blend-specific controlled human evidence identified in the curated record.

Each ingredient has its own evidence position in this registry, and none of them carries dependable controlled human evidence for the uses claimed here. Adding four such ingredients together does not add their evidence together — the mixture is a new, untested product.

Two vials labelled KLOW can contain different ingredients, different proportions and different levels of purity. Nothing about the name tells you what is inside a particular vial.

• Which ingredients are actually present, and in what proportions.
• Whether the ingredients are chemically stable together in one vial.
• Whether GHK-Cu, studied mainly as a topical cosmetic ingredient, behaves the same way when injected — this has not been established.
• Identity, purity and sterility of the finished mixture, which no regulator has vetted.

No regulator has approved KLOW, or any of its named ingredients as an injectable mixture, for any use. Products sold this way are unapproved and unvetted; that is a legal and supply-chain statement, not a finding that the mixture has been shown to be harmful.

• No controlled human safety dataset exists for the combined mixture.
• Interactions between the ingredients in one injection have not been characterised.
• Injectable products from unregulated supply carry contamination, mislabelling and dosing-error risks that are independent of what the molecules themselves do.